Search

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

Interview with Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health on the role of partnerships in driving innovation.

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

How Collaboration is Driving Innovation at Boehringer Ingelheim Animal Health

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care